Horizon Pharma PLC

HZNP

NASDAQ. Currency in USD

61.89 -0.80 ( -1.28% )

Real time prices: September 30

Market Cap.
14.26B
Beta (5Y monthly)
1.21
Price/Earnings
11.24
EPS (TTM)
5.57
Forward Dividend
0.00 (0.00%)
Ex-Dividend Date
Volume
2.04M
1y Target Est.
142.42
Day's Range
61.85
-
64.16
52 Week's Range
57.84
-
120.53

Historical Summary

Performance
EPS growth
Share Buybacks

About Horizon Pharma PLC

Sector
Healthcare
Industry
Drug Manufacturers-General
Website
https://www.horizontherapeutics.com
Exchange
NASDAQ (XNAS)
Shares Outstanding
226.82M
Employees
2015
Address
70 St. Stephen?s Green, Dublin, Ireland, 2
Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC.; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; and Arrowhead Pharmaceuticals, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland with additional offices in Deerfield, Illinois; Chicago, Illinois; Lake Forest, Illinois; South San Francisco, California; Washington, D.C.; Gaithersburg, Maryland; Rockville, Maryland; and Mannheim, Germany.

Latest news

Horizon (HZNP) Completes Enrollment in Phase IV TED Study
Horizon (HZNP) Completes Enrollment in Phase IV TED Study

Horizon (HZNP) completes enrollment in the phase IV study evaluating Tepezza for the treatment of...
By Zacks Investment Research - 2 days ago

Horizon's (HZNP) Phase II Sjogren's Syndrome Study Meets Goal
Horizon's (HZNP) Phase II Sjogren's Syndrome Study Meets Goal

Horizon's (HZNP) phase II study on dazodalibep for treating patients with Sjogren's syndrome meets the...
By Zacks Investment Research - 2 weeks ago

Immunovant (IMVT) Up More Than 20% in Past 3 Months: Here's Why
Immunovant (IMVT) Up More Than 20% in Past 3 Months: Here's Why

Immunovant's (IMVT) lead pipeline candidate, batoclimab, is being developed for treating myasthenia gravis, thyroid eye...
By Zacks Investment Research - 3 weeks ago

Horizon Therapeutics (HZNP) Down 9.2% Since Last Earnings Report: Can It Rebound?
Horizon Therapeutics (HZNP) Down 9.2% Since Last Earnings Report: Can It Rebound?

Horizon Therapeutics (HZNP) reported earnings 30 days ago. What's next for the stock? We take...
By Zacks Investment Research - 4 weeks ago

Horizon (HZNP) Marketed Drugs Aid Growth, Stiff Rivalry a Woe
Horizon (HZNP) Marketed Drugs Aid Growth, Stiff Rivalry a Woe

Horizon's (HZNP) portfolio of marketed drugs, including Tepezza and Krystexxa, aid growth. The company is...
By Zacks Investment Research - 5 weeks ago

Horizon (HZNP) Inks Collaboration Deal with Q32 Bio for ADX-914
Horizon (HZNP) Inks Collaboration Deal with Q32 Bio for ADX-914

Horizon (HZNP) enters into a collaboration and option agreement with Q32 Bio to develop the...
By Zacks Investment Research - 6 weeks ago

Immunovant (IMVT) Focus on Developing Autoimmune Disease Drug
Immunovant (IMVT) Focus on Developing Autoimmune Disease Drug

Immunovant (IMVT) remains focused on developing its lead pipeline candidate, batoclimab for treating several types...
By Zacks Investment Research - 6 weeks ago

Expert Ratings for Horizon Therapeutics
Expert Ratings for Horizon Therapeutics

Analysts have provided the following ratings for Horizon Therapeutics (NASDAQ:HZNP) within the last quarter: Bullish...
By Benzinga - 8 weeks ago